SCHEMBL758172

SCHEMBL758172

CC1CCC(N2CCOCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 3/20 0.42
OPRL1 P41146 2/20 0.41
ALOX15 P16050 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL3 Q96JM7 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
POLB P06746 1/20 0.36
CYP2A13 Q16696 1/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.35
IRAK4 Q9NWZ3 2/20 0.35
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735960 1.00 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15
SCHEMBL736465 1.00 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15
SCHEMBL7941629 0.92 L3MBTL3 (0.41) SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15
SCHEMBL23943467 0.88 KDM4E (0.44) ALDH1A1KDM4EALOX15MEN1KMT2A
SCHEMBL26112778 0.87 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1KDM4EOPRL1L3MBTL3
SCHEMBL26112782 0.87 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1KDM4EOPRL1L3MBTL3
SCHEMBL3168997 0.87
SCHEMBL22179798 0.86 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1OPRL1L3MBTL3L3MBTL1
SCHEMBL18727450 0.86 KDM4E (0.36) SMN1; SMN2ALDH1A1KDM4EOPRL1ALOX15
SCHEMBL26820274 0.86 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1OPRL1L3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
EP-2435432-B3 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE IRELAND UNLIMITED CO (BM) 2023-10-25 EP disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 US disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
EP-4223752-A1 DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Zhuhai Yufan Biotechnologies Co., Ltd (CN) 2023-08-09 EP disclosed
WO-2023142754-A1 EZH1/2 INHIBITOR, PREPARATION THEREOF, AND USE THEREOF IN ANTI-TUMOR THERAPY 江苏天士力帝益药业有限公司 2023-08-03 WO disclosed
US-20230241050-A1 APPLICATIONS OF HPK1 KINASE INHIBITOR IN PREVENTING AND/OR TREATING ANIMAL PATHOGEN INFECTION Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) 2023-08-03 US disclosed
EP-1773796-B1 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-03-03 EP disclosed
WO-2010015803-A1 DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R & D MANAGEMENT CO. LTD (JP) 2010-02-11 WO disclosed
EP-0953613-B1 Ink, ink-jet recording method using the same, and photopolymerization initiator CANON KK (JP) 2009-07-08 EP disclosed
US-20090163465-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
US-20090149438-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-11 US disclosed
US-20090143379-A1 Storage stable perfusion solution for dihydropteridinones BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 US disclosed
US-7521457-B2 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-21 US disclosed
WO-2007115933-A1 THIAZOLYLDIHYDROINDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
US-20070149562-A1 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-06-28 US disclosed
US-5215967-A AMINOACID DERIVATIVES INHIBITING RENIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 SMN1; SMN2 4113/4885ALDH1A1 2924/4885KDM4E 2228/4885
US-20090163465-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP SMN1; SMN2 2348/4885ALDH1A1 971/4885KDM4E 1758/4885
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS SMN1; SMN2 4001/4885ALDH1A1 1538/4885KDM4E 2994/4885
US-20090149438-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP SMN1; SMN2 2348/4885ALDH1A1 971/4885KDM4E 1758/4885
US-20090143379-A1 Storage stable perfusion solution for dihydropteridinones QDPR, F5, F12 SMN1; SMN2 2653/4885ALDH1A1 1200/4885KDM4E 4832/4885
US-20070149562-A1 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF MC5R, MC4R, OPRD1 SMN1; SMN2 3145/4885ALDH1A1 338/4885KDM4E 1965/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS SMN1; SMN2 4001/4885ALDH1A1 1538/4885KDM4E 2994/4885
US-20230241050-A1 APPLICATIONS OF HPK1 KINASE INHIBITOR IN PREVENTING AND/OR TREATING ANIMAL PATHOGEN INFECTION VRK1, STK3, DAPK1 SMN1; SMN2 4534/4885ALDH1A1 3599/4885KDM4E 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.